Increased plasma levels of interleukin-6 in sepsis [see comments]

Interleukin-6 (IL-6) is likely to be an important mediator of the inflammatory response. We measured levels of this cytokine in plasma samples from 37 patients with sepsis or septic shock obtained at the time of admission to the intensive care unit and related these levels to hemodynamic and biochemical parameters as well as to clinical outcome. In 32 of the 37 patients, increased levels of IL-6 were found, occasionally up to 7,500 times the normal level. The highest IL-6 levels were encountered in patients who suffered from septic shock (P value of the difference between patients with and without shock less than .0001). In addition, IL-6 significantly correlated with plasma lactate (P less than .0001), heart rate (P = .05) and, inversely, with mean arterial pressure (P = .01) and platelet counts (P = .0002). Significant correlations of IL-6 with the anaphylatoxins C3a (P = .0001) and C4a (P = .0002) and with the main inhibitor of the classical pathway of complement, C1-inhibitor (inverse correlation, P = .05), were also observed. IL-6 on admission appeared to be of prognostic significance: levels were higher in septic patients who subsequently died than in those who survived (P = .0003), in particular when only patients with septic shock were considered (P less than .0001). All nine septic patients with levels of less than 40 U/mL on admission survived, whereas 89% of the nine patients with levels exceeding 7,500 U/mL died. These data provide evidence for a role of IL-6 in the pathophysiology of septic shock. Further studies are needed to reveal whether IL-6 in sepsis is directly involved in mediating lethal complications or whether it is to be considered as an “alarm hormone” that reflects endothelial cell injury probably mediated by the anaphylatoxines.

[1]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[2]  W. R. Mccabe Serum complement levels in bacteremia due to gram-negative organisms. , 1973, The New England journal of medicine.

[3]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[4]  S. Tatter,et al.  Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. , 1989, Journal of immunology.

[5]  C. Hack,et al.  Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. , 1989, The American journal of medicine.

[6]  D. Belin,et al.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors , 1986, The Journal of experimental medicine.

[7]  A. Groeneveld,et al.  Hemodynamic determinants of mortality in human septic shock. , 1986, Surgery.

[8]  T. Raffin,et al.  Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. , 1988, The American review of respiratory disease.

[9]  T. Hirano,et al.  Induction of rat acute‐phase proteins by interleukin 6 in vivo , 1988, European journal of immunology.

[10]  L. Aarden,et al.  Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. , 1988, Clinical and experimental immunology.

[11]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[12]  L. Aarden,et al.  Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.

[13]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[14]  B. Hazenberg,et al.  The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. , 1988, Biochemical and biophysical research communications.

[15]  S. Clark,et al.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. , 1988, Journal of immunology.

[16]  R. Ulevitch,et al.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. , 1988, The Journal of clinical investigation.

[17]  C. Uyttenhove,et al.  Interleukin‐HP1‐related hybridoma and plasmacytoma growth factors induced by lipopolysaccharide in vivo , 1987, European journal of immunology.

[18]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[19]  F. Houssiau,et al.  Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. , 1988, Clinical and experimental immunology.

[20]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[21]  H. Baumann,et al.  Synthesis of hemopexin and cysteine protease inhibitor is coordinately regulated by HSF-II and interferon-beta 2 in rat hepatoma cells. , 1987, Biochemical and biophysical research communications.

[22]  P. Lansdorp,et al.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[24]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[25]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[26]  L. Aarden,et al.  Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. , 1988, Scandinavian journal of rheumatology.

[27]  J H Korn,et al.  Structure and expression of cDNA and genes for human interferon‐beta‐2, a distinct species inducible by growth‐stimulatory cytokines. , 1986, The EMBO journal.

[28]  A. Waage,et al.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.

[29]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[30]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Beutler,et al.  Cachectin: more than a tumor necrosis factor. , 1987, The New England journal of medicine.

[32]  W. Vogt Anaphylatoxins: possible roles in disease. , 1986, Complement.

[33]  G. Opdenakker,et al.  Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor. , 1985, European journal of biochemistry.

[34]  B. Beutler,et al.  The role of cachectin/TNF in endotoxic shock and cachexia. , 1988, Immunology today.

[35]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.

[36]  G. Opdenakker,et al.  Interleukin 1 and poly(rI) · poly(rC) induce production of a hybridoma growth factor by human fibroblasts , 1987, European journal of immunology.

[37]  L. Aarden,et al.  Interleukin 6 is involved in interleukin 1‐induced activities , 1988, European journal of immunology.